PSG Stock Overview
Manufactures and sells over-the-counter drugs and other healthcare products in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
PharmaSGP Holding SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €21.40 |
| 52 Week High | €29.50 |
| 52 Week Low | €17.70 |
| Beta | 0.019 |
| 11 Month Change | -6.96% |
| 3 Month Change | -6.96% |
| 1 Year Change | -21.90% |
| 33 Year Change | -4.04% |
| 5 Year Change | n/a |
| Change since IPO | -37.97% |
Recent News & Updates
Recent updates
Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings
May 06
Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio
Mar 02PharmaSGP Holding SE Just Beat Revenue Estimates By 25%
Dec 02One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically
Feb 16
We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential
Jan 26Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?
Dec 04Shareholder Returns
| PSG | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.6% | 0.3% | 0.8% |
| 1Y | -21.9% | -17.8% | 5.5% |
Return vs Industry: PSG underperformed the German Pharmaceuticals industry which returned -17.5% over the past year.
Return vs Market: PSG underperformed the German Market which returned 5.7% over the past year.
Price Volatility
| PSG volatility | |
|---|---|
| PSG Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: PSG has not had significant price volatility in the past 3 months.
Volatility Over Time: PSG's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 89 | Natalie Weigand | pharmasgp.com |
PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company’s pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for the treatment of hair loss; Dorisol for neuralgia (nerve pain), headaches, and migraines; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness, and mood swings; Deruba, a cream for skin redness; Lentisol that prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo.
PharmaSGP Holding SE Fundamentals Summary
| PSG fundamental statistics | |
|---|---|
| Market cap | €256.59m |
| Earnings (TTM) | €18.11m |
| Revenue (TTM) | €107.29m |
14.2x
P/E Ratio2.4x
P/S RatioIs PSG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSG income statement (TTM) | |
|---|---|
| Revenue | €107.29m |
| Cost of Revenue | €9.74m |
| Gross Profit | €97.56m |
| Other Expenses | €79.45m |
| Earnings | €18.11m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.51 |
| Gross Margin | 90.93% |
| Net Profit Margin | 16.88% |
| Debt/Equity Ratio | 163.9% |
How did PSG perform over the long term?
See historical performance and comparison